SMYD3 Homogeneous Assay Kit

Catalog #
52063
$1,125 *
Size: 384 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The SMYD3 Homogeneous Assay Kit is designed to measure SMYD3 (SET and MYND domain containing protein 3) activity for screening and profiling applications. The SMYD3 Homogeneous Assay Kit comes in a convenient 384-well AlphaLISA® format, with enough purified recombinant SMYD3/HSP90 complex, GST-tagged SMYD3 substrate, primary antibody and methylation assay buffer for 384 enzyme reactions.

Figure 1: SMYD3 Homogenous Assay Kit schematic.
A sample containing SMYD3/HSP90 complex is incubated with a substrate for four hours. This is followed by the addition of acceptor beads and primary antibody, and finally donor beads. Alpha-counts are then counted. Alpha-counts are proportional to SMYD3 methylase activity.

Need us to run inhibitor screens or profile your compounds against SMYD3? Check out our Methyltransferase Screening Services

Synonyms
Histone-lysine N-methyltransferase SMYD3, KMT3E, SET and MYND domain-containing protein 3, Zinc finger MYND domain-containing protein 1, ZMYND1, ZNFN3A1
Product Info
Storage and Usage
Citations
Assay Kit Format
AlphaLISA®
Materials Required But Not Supplied
  • AlphaLISA® anti-rabbit IgG acceptor beads (Perkin Elmer #AL104C)
  • AlphaScreen® Glutathione-conjugated donor beads (Perkin Elmer #6765300)
  • Optiplate-384 (PerkinElmer #6007290)  
  • AlphaScreen® microplate reader
Format
Catalog # Component Amount Storage
51110 SMYD3/HSP90* 2 x 50 µg -80°C
52120 100 µM
S-adenosylmethionine
2 x 250 µl -80°C
52140O3 Primary antibody 15-3 20 µl -80°C
  SMYD3 substrate 2 x 200 µl -80°C
  4x SMYD3 Assay Buffer 3 x 1 ml -20°C
  4x Detection Buffer 3D 2 ml -20°C
  0.5 mM DTT 200 µl -20°C
  Plate sealer   Room Temp

*The initial concentration of enzyme is lot-specific and will be indicated on the tube containing the protein.

UniProt #
Q9H7B4
Background

SMYD3, also known as SET (suppressor of variegation, enhancer of Zeste, Thithorax) and MYND (myeloid-Nervy-DEAF-1) domain-containing protein 3 is a lysine methyltransferase family member. It is involved in methylation of H3K4 and H4K5, but also of non-histone substrates such as VEGFR1 (vascular endothelial growth factor receptor 1), MAP3K2 (MAP3 kinase 2), AKT1 (protein kinase B) and HER2 (human epidermal growth factor receptor 2). In adults it is found in platelets, testis, CD8+ T-cells, and at very low levels in the heart, bladder, prostate, spinal cord and retina. It is overexpressed in several cancer types, such as liver and breast cancer, and plays a role in disease progression via its substrates. For instance, SMYD3 activates AKT1 by methylation on lysine 14, resulting in cell growth, survival and neovascularization. The low or absence expression of SMYD3 in normal tissues makes it a promising cancer therapy candidate. Several inhibitors are undergoing clinical trials, but further studies are necessary. A deep understanding of the role of SMYD3 and identification of potent specific inhibitors will advance the cancer therapy field.

References

Dillon S.C., et al. 2005 Genome Biology 6:227. 
Silva F.P., et al. 2008 Oncogene 27:2686.
Bernard B., et al., 2021 Clin Epigenetics 13:45.